New hope for Tough-to-Treat lung cancer in early trial
NCT ID NCT07391813
Summary
This study is testing a new drug called SNB-101 for people with advanced small cell lung cancer that has continued to grow after standard chemotherapy. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it might help control the cancer. Participants will receive the drug by IV infusion every 28-day cycle.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENT IS NOT SUITABLE FOR COMPLETE SURGICAL RESECTION WITH A CYTOLOGICALLY OR HISTOLOGICALLY CONFIRMED SMALL CELL LUNG CANCER(SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Institute for Pulmonary Diseases of Vojvodina
RECRUITINGKamenitz, 21204, Serbia
Conditions
Explore the condition pages connected to this study.